About Merida Biosciences
Merida Biosciences is a Cambridge, MA-based biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases. The company's protein engineering platform generates unique Fc therapeutics that identify and bind specific pathogenic antibodies, targeting them for rapid elimination while sparing healthy immune components. Its lead programs address Graves' disease, allergy, and primary membranous nephropathy.
Company details
Funding
Total raised
$121M
Last stage
Series A
Investors
Founders
Dario Gutierrez
Ph.D. in molecular physiology and biophysics from Vanderbilt University. Previously Entrepreneur-in-Residence at Third Rock Ventures, VP of Discovery Research & Innovation at TCR2 Therapeutics, and Director & Head of Investigational Biology at the Merck Exploratory Science Center.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.